Table 1 Association between PD-L1 expression status and clinical features
From: Unraveling EGFR-TKI resistance in lung cancer with high PD-L1 or TMB in EGFR-sensitive mutations
Characteristics | All (N = 339) | PD-L1 expression level | aP-value | ||
|---|---|---|---|---|---|
High (N = 74) | Medium (N = 79) | Negative (N = 186) | |||
Pathological type, n (%) | 0.398 | ||||
Adenocarcinoma | 295 (87.0%) | 62 (83.8%) | 67 (84.8%) | 166 (89.2%) | |
Squamous cell carcinoma | 44 (13.0%) | 12 (16.2%) | 12 (15.2%) | 20 (10.8%) | |
Gender, n (%) | 0.069 | ||||
Female | 169 (49.9%) | 32 (43.2%) | 48 (60.8%) | 89 (47.8%) | |
Male | 170 (50.1%) | 42 (56.8%) | 31 (39.2%) | 97 (52.2%) | |
Age at diagnosis in years, n (%) | 0.026 | ||||
60- (< 60) | 131 (38.6%) | 33 (44.6%) | 38 (48.1%) | 60 (32.3%) | |
60+ (≥ 60) | 208 (61.4%) | 41 (55.4%) | 41 (51.9%) | 126 (67.7%) | |
EGFRstatus, n (%) | 0.138 | ||||
E19del | 66 (19.5%) | 12 (16.2%) | 18 (22.8%) | 36 (19.4%) | |
L858R | 102 (30.1%) | 14 (18.9%) | 25 (31.6%) | 63 (33.9%) | |
other | 27 (8.0%) | 8 (10.8%) | 4 (5.1%) | 16 (8.6%) | |
Wild type | 144 (42.5%) | 40 (54.1%) | 32 (40.5%) | 71 (38.2%) | |
TMB status, n (%) | 0.003 | ||||
TMB-H (≥ 4.4 muts/Mb) | 110 (32.4%) | 36 (48.6%) | 24 (30.4%) | 50 (26.9%) | |
TMB-L (< 4.4 muts/Mb) | 229 (67.6%) | 38 (51.4%) | 55 (69.6%) | 136 (73.1%) | |
MSI status, n (%) | 0.117 | ||||
MSI-H | 3 (0.9%) | 1 (1.4%) | 2 (2.5%) | 0 (0.0%) | |
MSS | 336 (99.1%) | 73 (98.6%) | 77 (97.5%) | 186 (100.0%) | |